Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Details 2)

v2.4.0.8
Composition of Certain Financial Statement Captions (Details 2) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended 6 Months Ended
Jun. 30, 2014
Aug. 31, 2013
OPKO Biologics
Jun. 30, 2014
Pharmaceutical
CURNA
Jun. 30, 2014
Pharmaceutical
Exakta-OPKO
Jun. 30, 2014
Pharmaceutical
OPKO Chile
Jun. 30, 2014
Pharmaceutical
OPKO Spain
Jun. 30, 2014
Pharmaceutical
FineTech
Jun. 30, 2014
Pharmaceutical
SciVac
Jun. 30, 2014
Pharmaceutical
OPKO Renal
Jun. 30, 2014
Pharmaceutical
OPKO Biologics
Jun. 30, 2014
Diagnostics
Claros
Jun. 30, 2014
Diagnostics
OPKO Lab
Goodwill [Roll Forward]                        
Beginning balance $ 226,373 [1] $ 139,784 $ 4,827 $ 113 $ 6,102 $ 9,075 $ 11,698 $ 1,740 $ 2,069 $ 139,784 $ 17,977 $ 32,988
Acquisitions 0   0 0 0 0 0 0 0 0 0 0
Foreign exchange, other (372)   0 0 (310) (79) 0 17 0 0 0 0
Ending balance $ 226,001 [1] $ 139,784 $ 4,827 $ 113 $ 5,792 $ 8,996 $ 11,698 $ 1,757 $ 2,069 $ 139,784 $ 17,977 $ 32,988
[1] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.